Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Rheumatol Int ; 38(8): 1565-1570, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29754327

RESUMO

Vascular involvement in IgG4-related disease (IgG4-RD), is a well-recognized feature and large vessel commitment, especially the aorta, can be the only manifestation of the disease. Being a newly recognized disease, its diagnosis and workup still represents a challenge in clinical practice. A 47-year-old-man with two aortic aneurysms ruptures, one at abdominal and the other at thoracic level, was referred to our rheumatology department. The initial analysis of the surgical specimen obtained 3 years earlier revealed a nonspecific aortitis. Re-evaluation of the biopsy with immunohistology now demonstrated the presence of IgG4 deposits. Evidence-based recommendations regarding diagnosis, treatment and follow-up of IgG4-related large-vessel involvement are lacking. In this particular case, histopathology were crucial. The authors review and discuss vascular involvement in IgG4-RD and respective treatment options.


Assuntos
Aneurisma da Aorta Abdominal/imunologia , Aneurisma da Aorta Torácica/imunologia , Ruptura Aórtica/etiologia , Aortite/imunologia , Doença Relacionada a Imunoglobulina G4/imunologia , Idoso , Aneurisma da Aorta Abdominal/patologia , Aneurisma da Aorta Torácica/patologia , Ruptura Aórtica/imunologia , Ruptura Aórtica/cirurgia , Aortite/sangue , Aortite/complicações , Aortite/tratamento farmacológico , Biomarcadores/sangue , Feminino , Humanos , Doença Relacionada a Imunoglobulina G4/sangue , Doença Relacionada a Imunoglobulina G4/diagnóstico , Doença Relacionada a Imunoglobulina G4/tratamento farmacológico , Fatores Imunológicos/administração & dosagem , Masculino , Pessoa de Meia-Idade , Plasmócitos/imunologia , Rituximab/administração & dosagem
2.
J Rheumatol ; 44(4): 512-518, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28202742

RESUMO

OBJECTIVE: The term "invalidation" refers to the patients' perception that their medical condition is not recognized by the social environment. Invalidation can be a major issue in patients' lives, adding a significant burden to symptoms and limitations while increasing the risk of physical and psychological disability. In this study in patients with rheumatic diseases, we investigated the relationship between invalidation and sociodemographic, clinical, psychological, and personality characteristics. METHODS: This international cross-sectional study included 562 adults with rheumatoid arthritis (n = 124), spondyloarthritis (n = 85), systemic lupus erythematosus (n = 112), or fibromyalgia (FM; n = 241). Assessed were the family and health professionals subscales of the Illness Invalidation Inventory (3*I), happiness (Subjective Happiness Scale), personality (Ten-Item Personality Inventory), pain, and loneliness (numerical rating scales). Univariate and multivariate analyses were used to test different models. RESULTS: Invalidation occurred in all rheumatic diseases, but patients with FM reported the most invalidation. Including all correlated variables in the multivariate model, pain remained as a determinant of invalidation by health professionals, but not by family. Regarding psychological variables, loneliness remained as a determinant of invalidation by family, but not by health professionals. FM and low levels of happiness, agreeableness, and conscientiousness were associated with invalidation while taking account of other variables. CONCLUSION: Invalidation occurs in all rheumatic diseases and patients with FM experience the most invalidation. Psychological factors (happiness, agreeableness, and conscientiousness), loneliness, and pain intensity are associated with invalidation, irrespective of the rheumatic disease and may deserve dedicated interventions.


Assuntos
Artrite Reumatoide/psicologia , Fibromialgia/psicologia , Lúpus Eritematoso Sistêmico/psicologia , Meio Social , Apoio Social , Espondilartrite/psicologia , Adulto , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Inquéritos e Questionários
3.
Biomed Res Int ; 2015: 490295, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25834819

RESUMO

BACKGROUND: The aim of our work was to replicate, in a Southern European population, the association reported in Northern populations between PTPRC locus and response to anti-tumor necrosis factor (anti-TNF) treatment in rheumatoid arthritis (RA). We also looked at associations between five RA risk alleles and treatment response. METHODS: We evaluated associations between anti-TNF treatment responses assessed by DAS28 change and by EULAR response at six months in 383 Portuguese patients. Univariate and multivariate linear and logistic regression analyses were performed. In a second step to confirm our findings, we pooled our population with 265 Spanish patients. RESULTS: No association was found between PTPRC rs10919563 allele and anti-TNF treatment response, neither in Portuguese modeling for several clinical variables nor in the overall population combining Portuguese and Spanish patients. The minor allele for RA susceptibility, rs3761847 SNP in TRAF1/C5 region, was associated with a poor response in linear and logistic univariate and multivariate regression analyses. No association was observed with the other allellic variants. Results were confirmed in the pooled analysis. CONCLUSION: This study did not replicate the association between PTPRC and the response to anti-TNF treatment in our Southern European population. We found that TRAF1/C5 risk RA variants potentially influence anti-TNF treatment response.


Assuntos
Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/genética , Estudos de Associação Genética , Antígenos Comuns de Leucócito/genética , Fator 1 Associado a Receptor de TNF/genética , Adalimumab/administração & dosagem , Adulto , Idoso , Alelos , Anticorpos Monoclonais/administração & dosagem , Artrite Reumatoide/patologia , Etanercepte/administração & dosagem , Cadeias HLA-DRB1/genética , Humanos , Infliximab/administração & dosagem , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único , Proteína Tirosina Fosfatase não Receptora Tipo 22/genética
4.
Rheumatology (Oxford) ; 53(1): 85-9, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24067885

RESUMO

OBJECTIVE: SLE has a relapsing-remitting course with disease activity flares over time. This study aims to identify clinical predictors of SLE flares. METHODS: This prospective cohort study over 24 months included all SLE patients on follow-up at one academic lupus clinic. Flare was defined as an increase in SLEDAI-2K score ≥4 points. Baseline clinical and demographic parameters were compared using survival analysis for time-to-flare outcome with univariate log-rank tests. Variables with significant differences were further evaluated as predictors with multivariate Cox regression models adjusting for potential confounding or contributing factors and hazard ratio (HR) calculation. RESULTS: A total of 202 SLE patients were included. Over the follow-up period, 1083 visits were documented and 16.8% of patients presented with flares. In multivariate analysis, the following parameters emerged as flare predictors: SLE diagnosis up to 25 years of age (HR = 2.14, P = 0.03), lupus nephritis previous to baseline visit (HR = 4.78, P < 0.0001) and immunosuppressor treatment for severe SLE (HR = 3.22, P < 0.001). Baseline disease activity, disease duration and treatment with prednisone or HCQ were not predictive factors. CONCLUSION: Patients with an SLE diagnosis before age 25 years, lupus nephritis or immunosuppressor treatment for severe SLE present greater HRs for flares, suggesting the need for tighter clinical monitoring. Current immunosuppressive strategies seem to be inefficient in providing flare prevention.


Assuntos
Imunossupressores/uso terapêutico , Lúpus Eritematoso Sistêmico/diagnóstico , Adulto , Biópsia , Feminino , Seguimentos , Humanos , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Masculino , Estudos Prospectivos , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento
5.
Ann N Y Acad Sci ; 1069: 168-82, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16855144

RESUMO

Estrogens at physiological concentrations are thought to play an immune-stimulating role, whereas androgens have an anti-inflammatory impact. However, their role on cytokine secretion in the presence or absence of cortisol has not been investigated. Furthermore, the role of hydroxylated estrogens downstream of 17beta-estradiol (E2) on secretion of tumor necrosis factor (TNF) is not known. In this study on peripheral blood leukocytes of healthy male subjects, we scrutinized the influence of prior sex hormones (for 24 h) with and without later addition of cortisol (for another 24 h) on stimulated secretion of TNF, IL-2, IL-4, IL-6, IL-10, and interferon-gamma (IFN-gamma). E2 stabilized or increased immune stimuli-induced secretion of TNF, IL-2, IL-4, IL-6, IL-10, and IFNgamma in relation to testosterone. Testosterone, in contrast, inhibited (IL-2, IL-4, IL-10) or tended to inhibit stimulated secretion of these cytokines (TNF, IFNgamma). This effect of E2 was pronounced at a concentration of 10(-10) M (testosterone: 10(-7) M) in the presence of cortisol. E2 (10(-8) M, 10(-10) M) and testosterone (10(-7) M) did not change glucocorticoid receptor expression. The downstream estrogens 2OH-estradiol(one), 4OH-estradiol(one), and 16OH-estradiol(one) did not stimulate TNF secretion at 10(-10) M, but even inhibited its secretion at 10(-11) M. However, the combination of 16OH-estradiol(one) on one side and 2OH-estradiol(one) or 4OH-estradiol(one) on the other side markedly stimulated TNF secretion that was only observable in the presence of cortisol. In conclusion, at physiological concentrations, E2 and a combination of downstream estrogens stabilized or increased immune stimuli-induced TNF secretion. These effects are dependent on the presence of physiological concentrations of cortisol. This study underlines the proinflammatory role of E2, which is probably dependent on conversion to a proinflammatory cocktail of downstream estrogens and the presence of cortisol.


Assuntos
Citocinas/metabolismo , Estradiol/farmacologia , Estrogênios/farmacologia , Hidrocortisona/farmacologia , Leucócitos/efeitos dos fármacos , Leucócitos/metabolismo , Testosterona/farmacologia , Adulto , Humanos , Masculino , Receptores de Glucocorticoides/metabolismo
6.
Ann N Y Acad Sci ; 966: 68-72, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12114260

RESUMO

Evidence from experimental animal studies show that sex hormones influence the glucocorticoid response to a variety of inflammatory and noninflammatory stimuli. In this study we assessed gender differences in the response of ACTH and cortisol in normal young male and female humans following intravenous infusion of human IL-6 in various dosages. Males presented a significantly stronger ACTH production in response to IL-6 than females. Peak cortisol response, however, was similar in males and females. Cortisol/ACTH ratios were significantly higher in females than in males, both at baseline and after each of the IL-6 dosages. These results suggest that an effective glucocorticoid response requires similar levels of IL-6 in males and females. However, they also suggest that the adrenals of males and females have different sensitivities to ACTH (higher in females) and possibly also to direct IL-6 stimulation.


Assuntos
Corticosteroides/metabolismo , Córtex Suprarrenal/metabolismo , Hormônio Adrenocorticotrópico/metabolismo , Hidrocortisona/metabolismo , Interleucina-6/farmacologia , Caracteres Sexuais , Córtex Suprarrenal/efeitos dos fármacos , Corticosteroides/sangue , Hormônio Adrenocorticotrópico/sangue , Adulto , Feminino , Fase Folicular , Humanos , Hidrocortisona/sangue , Infusões Intravenosas , Interleucina-6/administração & dosagem , Masculino , Sistema Hipófise-Suprarrenal/fisiologia , Taxa Secretória/efeitos dos fármacos
7.
Ann N Y Acad Sci ; 966: 158-65, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12114269

RESUMO

Gender and sex hormones are strongly related to the incidence and progression of autoimmune rheumatic diseases. Although sex steroids have been shown to have direct effects on the immune system, their influence in vivo may be mediated via interactions with third party systems including the hypothalamic-pituitary-adrenal axis. Such interactions are well demonstrated in experimental animals. In humans, there is increasing, although indirect, evidence that these interactions also occur. Possible interactions at the cell and gene level, with mutual antagonism or synergy between cortico- and gonadal steroids, open new exciting hypotheses that await clarification.


Assuntos
Artrite Reumatoide/fisiopatologia , Doenças Autoimunes/fisiopatologia , Glucocorticoides/fisiologia , Hormônios Esteroides Gonadais/fisiologia , Animais , Artrite Reumatoide/tratamento farmacológico , Doenças Autoimunes/tratamento farmacológico , Citocinas/metabolismo , Método Duplo-Cego , Interações Medicamentosas , Terapia de Reposição de Estrogênios , Feminino , Glucocorticoides/uso terapêutico , Hormônios Esteroides Gonadais/uso terapêutico , Humanos , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Sistema Hipotálamo-Hipofisário/fisiopatologia , Masculino , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Sistema Hipófise-Suprarrenal/fisiopatologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Ratos , Receptores de Esteroides/efeitos dos fármacos , Receptores de Esteroides/fisiologia , Transdução de Sinais/efeitos dos fármacos , Método Simples-Cego
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA